Autres langues BioArctic AB

Actions

BIOA B

SE0010323311

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 11/06/2024			Varia. 5j.	Varia. 1 janv.
218,6 ^SEK	-5,45 %		-10,04 %	-18,37 %

10/06	Le jour de la marmotte
10/06	En Direct des Marchés : Stellantis, Crédit Agricole, LVMH, Volvo, Microsoft, Apple, Southwest Airlines...

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioArctic AB - FDA accepts filing of Leqembi sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease	15:58
Global markets live: ABB, Roche, Microsoft, Apple, Tesla...	10/06
Borsa di Italia: Il giorno della marmotta	10/06
Bolsa de Madrid: El día de la marmota	10/06
BioArctic Reports US FDA's Acceptance of Biologics License Application for Leqembi IV Maintenance Dosing	10/06
FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease	10/06
Nordic Stocks Dropped Wednesday; NEL Fell Furthest	29/05
Nordic Shares Moved Upward Monday; Sinch Led Increases	27/05
BioArctic, Eisai's Azlheimer’s Disease Drug Wins Regulatory Nod in South Korea	24/05
Leqembi[®] approved for the treatment of Alzheimer's disease in South Korea	24/05
BioArctic AB Approves Leqembi [®] for the Treatment of Alzheimer's Disease in South Korea	24/05
Bulletin from the Annual General Meeting in BioArctic AB (publ)	22/05
Interim Report for the period January - March 2024	17/05
BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2024	17/05
Nordic Shares Moved Upward Wednesday; BioArctic Series B Topped Leaders	15/05
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	15/05
Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 - March 2025)	15/05
Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing	15/05
Invitation to presentation of BioArctic's first quarter report for January - March 2024 on May 17 at 9:30 a.m. CET	07/05
BioArctic AB - Leqembi revenue totaled JPY 2.83 billion in the first quarter 2024	25/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues BioArctic AB

Actions

BIOA B

SE0010323311

Autres langues

Filtres